Aaron Craig Burns

USPTO Granted Patents = 18 (Patent Applications = 17)

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 5 (Patent Applications = 20)

Average Co-Inventor Count = 7.4

ph-index = 3

Forward Citations = 20(Granted Patents)

Company Filing History:

14 out of 38

Mirati Therapeutics, Inc.

Dart Neuroscience, LLC

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

18 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12421228 - Naphthyridine derivatives as PRC2 inhibitors (2025-09-23),

2. 12371435 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2025-07-29),

3. 12304915 - SOS1 inhibitors (2025-05-20),

4. 12252493 - Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer (2025-03-18),

5. 12006325 - Substituted furanopyrimidine compounds as PDE1 inhibitors (2024-06-11),

6. 11964989 - KRas G12D inhibitors (2024-04-23),

7. 11702418 - SOS1 inhibitors (2023-07-18),

8. 11548888 - KRas G12C inhibitors (2023-01-10),

9. 11492351 - MTA-cooperative PRMT5 inhibitors (2022-11-08),

10. 11485738 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2022-11-01),

11. 11479551 - MTA-cooperative PRMT5 inhibitors (2022-10-25),

12. 11453683 - KRas G12D inhibitors (2022-09-27),

13. 11434247 - Substituted furanopyrimidine compounds as PDE1 inhibitors (2022-09-06),

14. 11220509 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2022-01-11),

15. 11091495 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2021-08-17),

Title: The Inventor Spotlight: Aaron Craig Burns

Introduction:

In the realm of innovation and patenting, Aaron Craig Burns stands out as a prolific inventor hailing from San Diego, California. With a remarkable 13 patents under his belt, Burns has made significant contributions to the field of pharmaceuticals, particularly in the area of cancer treatment.

Latest Patents:

Aaron Craig Burns' latest patents showcase his expertise in developing cutting-edge therapies for cancer treatment. His inventions include KRas G12D inhibitors - compounds designed to inhibit the activity of KRas G12D, as well as SOS1 inhibitors - compounds that target Son of sevenless homolog 1 (SOS1) activity. These patents highlight Burns' commitment to advancing medical science and improving patient outcomes.

Career Highlights:

Throughout his career, Aaron Craig Burns has made his mark in renowned companies such as Mirati Therapeutics, Inc. and Array Biopharma Inc. His innovative work has helped these organizations stay at the forefront of pharmaceutical research and development. Burns' dedication to his craft and his relentless pursuit of novel solutions have earned him a stellar reputation in the industry.

Collaborations:

Collaboration is key in the world of innovation, and Aaron Craig Burns has had the privilege of working alongside talented individuals like Matthew Arnold Marx and John Michael Ketcham. Together, they have combined their expertise to push the boundaries of scientific discovery and bring about transformative changes in cancer therapy.

Conclusion:

In conclusion, Aaron Craig Burns emerges as a trailblazer in the field of pharmaceutical innovation. His groundbreaking patents and successful collaborations underscore his passion for driving progress in cancer treatment. As he continues to push the boundaries of scientific knowledge, Burns remains a beacon of inspiration for aspiring inventors and researchers alike.

This text is generated by artificial intelligence and may not be accurate.